"Our preliminary experience has been overwhelmingly positive. The THOR DD
II device is very simple to use and calibrate and is quite predictable in its
function and effect. Wounds are healing more rapidly than, we have noted, in
work with other devices..., although the wounds are indeed healing with LLLT
applied using the appropriate parameters/dosimetry. It is our belief that
these devices are an important adjunct. My personal bias would be to apply
this technology to patients early; that is, to treat them at the first sign
of a wound or injury. We are continuing our clinical and laboratory
investigations aimed at elucidating the mechanisms and utility of
photobiomodulation in humans."

The British Medical Journal (BMJ), The Lancet, the International Association for the Study of Pain (IASP), the World Health Organisation (WHO), the Multinational Association for Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO)